Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19

Saved in:
Bibliographic Details
Published inFrontiers in medicine Vol. 8; p. 743325
Main Authors Alape-Girón, Alberto, Moreira-Soto, Andrés, Arguedas, Mauricio, Brenes, Hebleen, Buján, Willem, Corrales-Aguilar, Eugenia, Díaz, Cecilia, Echeverri, Ann, Flores-Díaz, Marietta, Gómez, Aarón, Hernández, Andrés, Herrera, María, León, Guillermo, Macaya, Román, Molina-Mora, José Arturo, Mora, Javier, Narayanan, Aarthi, Sanabria, Alfredo, Sánchez, Andrés, Sánchez, Laura, Segura, Álvaro, Segura, Eduardo, Solano, Daniela, Soto, Claudio, Stynoski, Jennifer L., Vargas, Mariángela, Villalta, Mauren, Drexler, Jan Felix, Gutiérrez, José María
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 06.09.2021
Subjects
convalescent plasma
COVID-19
heterologous antibodies
hyperimmune polyclonal antibodies
Medicine
passive immunotherapy
SARS-CoV-2
COVID-19
SARS-CoV-2
heterologous antibodies
hyperimmune polyclonal antibodies
passive immunotherapy
convalescent plasma
monoclonal antibodies
Online AccessGet full text

Cover

Author Segura, Álvaro
Brenes, Hebleen
Macaya, Román
Herrera, María
Moreira-Soto, Andrés
Flores-Díaz, Marietta
Stynoski, Jennifer L.
Echeverri, Ann
Solano, Daniela
Alape-Girón, Alberto
Díaz, Cecilia
Corrales-Aguilar, Eugenia
León, Guillermo
Mora, Javier
Sanabria, Alfredo
Vargas, Mariángela
Buján, Willem
Soto, Claudio
Villalta, Mauren
Gómez, Aarón
Segura, Eduardo
Sánchez, Andrés
Sánchez, Laura
Hernández, Andrés
Arguedas, Mauricio
Molina-Mora, José Arturo
Drexler, Jan Felix
Narayanan, Aarthi
Gutiérrez, José María
AuthorAffiliation 6 Research Center for Tropical Diseases, School of Microbiology, University of Costa Rica , San Pedro , Costa Rica
3 Institute of Virology, Charité Medical University of Berlin , Berlin , Germany
5 Caja Costarricense del Seguro Social , San Jose , Costa Rica
4 Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud, Ministry of Health , Cartago , Costa Rica
7 National Center for Biodefense and Infectious Diseases, College of Science, George Mason University , Fairfax, VA , United States
1 Instituto Clodomiro Picado, School of Microbiology, University of Costa Rica , San Pedro , Costa Rica
2 School of Medicine University of Costa Rica , San Pedro , Costa Rica
AuthorAffiliation_xml – name: 6 Research Center for Tropical Diseases, School of Microbiology, University of Costa Rica , San Pedro , Costa Rica
– name: 1 Instituto Clodomiro Picado, School of Microbiology, University of Costa Rica , San Pedro , Costa Rica
– name: 3 Institute of Virology, Charité Medical University of Berlin , Berlin , Germany
– name: 7 National Center for Biodefense and Infectious Diseases, College of Science, George Mason University , Fairfax, VA , United States
– name: 2 School of Medicine University of Costa Rica , San Pedro , Costa Rica
– name: 4 Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud, Ministry of Health , Cartago , Costa Rica
– name: 5 Caja Costarricense del Seguro Social , San Jose , Costa Rica
Author_xml – sequence: 1
  givenname: Alberto
  surname: Alape-Girón
  fullname: Alape-Girón, Alberto
– sequence: 2
  givenname: Andrés
  surname: Moreira-Soto
  fullname: Moreira-Soto, Andrés
– sequence: 3
  givenname: Mauricio
  surname: Arguedas
  fullname: Arguedas, Mauricio
– sequence: 4
  givenname: Hebleen
  surname: Brenes
  fullname: Brenes, Hebleen
– sequence: 5
  givenname: Willem
  surname: Buján
  fullname: Buján, Willem
– sequence: 6
  givenname: Eugenia
  surname: Corrales-Aguilar
  fullname: Corrales-Aguilar, Eugenia
– sequence: 7
  givenname: Cecilia
  surname: Díaz
  fullname: Díaz, Cecilia
– sequence: 8
  givenname: Ann
  surname: Echeverri
  fullname: Echeverri, Ann
– sequence: 9
  givenname: Marietta
  surname: Flores-Díaz
  fullname: Flores-Díaz, Marietta
– sequence: 10
  givenname: Aarón
  surname: Gómez
  fullname: Gómez, Aarón
– sequence: 11
  givenname: Andrés
  surname: Hernández
  fullname: Hernández, Andrés
– sequence: 12
  givenname: María
  surname: Herrera
  fullname: Herrera, María
– sequence: 13
  givenname: Guillermo
  surname: León
  fullname: León, Guillermo
– sequence: 14
  givenname: Román
  surname: Macaya
  fullname: Macaya, Román
– sequence: 15
  givenname: José Arturo
  surname: Molina-Mora
  fullname: Molina-Mora, José Arturo
– sequence: 16
  givenname: Javier
  surname: Mora
  fullname: Mora, Javier
– sequence: 17
  givenname: Aarthi
  surname: Narayanan
  fullname: Narayanan, Aarthi
– sequence: 18
  givenname: Alfredo
  surname: Sanabria
  fullname: Sanabria, Alfredo
– sequence: 19
  givenname: Andrés
  surname: Sánchez
  fullname: Sánchez, Andrés
– sequence: 20
  givenname: Laura
  surname: Sánchez
  fullname: Sánchez, Laura
– sequence: 21
  givenname: Álvaro
  surname: Segura
  fullname: Segura, Álvaro
– sequence: 22
  givenname: Eduardo
  surname: Segura
  fullname: Segura, Eduardo
– sequence: 23
  givenname: Daniela
  surname: Solano
  fullname: Solano, Daniela
– sequence: 24
  givenname: Claudio
  surname: Soto
  fullname: Soto, Claudio
– sequence: 25
  givenname: Jennifer L.
  surname: Stynoski
  fullname: Stynoski, Jennifer L.
– sequence: 26
  givenname: Mariángela
  surname: Vargas
  fullname: Vargas, Mariángela
– sequence: 27
  givenname: Mauren
  surname: Villalta
  fullname: Villalta, Mauren
– sequence: 28
  givenname: Jan Felix
  surname: Drexler
  fullname: Drexler, Jan Felix
– sequence: 29
  givenname: José María
  surname: Gutiérrez
  fullname: Gutiérrez, José María
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34552950$$D View this record in MEDLINE/PubMed
BookMark eNp1kk1v1DAQhiNUREvpnRPykQNZEn8kNgeksHzsSpWKWKi4WWNnvE3ljbdOttL-DX4xDtuiFomTx_Y7z6vRvM-zoz70mGUvy2LGmFRv3QbbGS1oOas5Y1Q8yU4oVVUuhfx59KA-zs6G4booijKJeMmeZceMC0GVKE6yXwscMQYf1mE3kMV-i7HbbHY9kq_B760PPXjS9GNnQtvhQJo1dP0wklXzbZXPw2VO35GGfIgBWjIPtxhhjW9I41yILRifauhbsrLgp1uCjphgibmcXMJ4lTq2e5LkZH5xufyYl-pF9tSBH_Ds7jzNfnz-9H2-yM8vviznzXlueUXHHBmvSuWUVQJAOcNtbQ1UlhsDXMhKSttK1nJrpHSOujqNLBF4qZhEBzU7zZYHbhvgWm_T3BD3OkCn_zyEuNYQx8561Ko11iB1BTWOowBTKFZji9y1ijLgifX-wNruTFqLTUNG8I-gj3_67kqvw62WXBR1JRPg9R0ghpsdDqPedINF76HHtBlNRS0kVaWcpK8eev01uV9qElQHgY1hGCI6bbsRxi5M1p3XZaGnAOkpQHoKkD4EKDUW_zTes__b8hvmH8ts
CitedBy_id crossref_primary_10_1016_j_jviromet_2024_115062
crossref_primary_10_1007_s40262_024_01351_w
crossref_primary_10_1038_s41598_022_07793_1
crossref_primary_10_1016_j_clim_2022_108981
crossref_primary_10_1080_17460441_2022_1995352
crossref_primary_10_1080_14712598_2022_2078160
crossref_primary_10_3390_cancers14051325
Cites_doi 10.1016/j.eclinm.2021.100926
10.1016/j.eclinm.2021.100843
10.1111/bcp.12739
10.1016/j.cell.2021.02.026
10.1038/s41591-021-01294-w
10.1128/mBio.03372-20
10.1080/21645515.2021.1940652
10.12688/wellcomeopenres.15990.1
10.1038/s41541-020-00256-6
10.1016/j.toxicon.2011.11.017
10.1111/vox.12964
10.1016/j.annemergmed.2019.02.007
10.3389/fmed.2021.684151
10.1038/s41577-021-00542-x
10.1111/trf.16378
10.1016/j.toxicon.2020.08.002
10.3390/v13071192
10.1002/btpr.3139
10.1111/vox.12939
10.1038/s41598-021-89242-z
10.1371/journal.pntd.0000767
10.1016/j.chom.2021.02.010
10.1093/infdis/jiu396
10.1038/s41586-021-03777-9
10.1056/NEJMoa1103975
10.1038/s41579-021-00573-0
10.1038/s41541-020-0209-2
10.1016/j.antiviral.2020.104868
10.1016/j.biologicals.2004.07.001
10.4269/ajtmh.21-0200
10.1016/j.cell.2021.03.013
10.1101/2021.06.12.448080
10.3390/vaccines9060538
10.1016/j.meegid.2021.104998
10.1016/j.toxicon.2013.09.010
10.2217/imt-2020-0263
10.1016/j.intimp.2020.107220
ContentType Journal Article
Copyright Copyright © 2021 Alape-Girón, Moreira-Soto, Arguedas, Brenes, Buján, Corrales-Aguilar, Díaz, Echeverri, Flores-Díaz, Gómez, Hernández, Herrera, León, Macaya, Molina-Mora, Mora, Narayanan, Sanabria, Sánchez, Sánchez, Segura, Segura, Solano, Soto, Stynoski, Vargas, Villalta, Drexler and Gutiérrez. 2021 Alape-Girón, Moreira-Soto, Arguedas, Brenes, Buján, Corrales-Aguilar, Díaz, Echeverri, Flores-Díaz, Gómez, Hernández, Herrera, León, Macaya, Molina-Mora, Mora, Narayanan, Sanabria, Sánchez, Sánchez, Segura, Segura, Solano, Soto, Stynoski, Vargas, Villalta, Drexler and Gutiérrez
Copyright_xml – notice: Copyright © 2021 Alape-Girón, Moreira-Soto, Arguedas, Brenes, Buján, Corrales-Aguilar, Díaz, Echeverri, Flores-Díaz, Gómez, Hernández, Herrera, León, Macaya, Molina-Mora, Mora, Narayanan, Sanabria, Sánchez, Sánchez, Segura, Segura, Solano, Soto, Stynoski, Vargas, Villalta, Drexler and Gutiérrez. 2021 Alape-Girón, Moreira-Soto, Arguedas, Brenes, Buján, Corrales-Aguilar, Díaz, Echeverri, Flores-Díaz, Gómez, Hernández, Herrera, León, Macaya, Molina-Mora, Mora, Narayanan, Sanabria, Sánchez, Sánchez, Segura, Segura, Solano, Soto, Stynoski, Vargas, Villalta, Drexler and Gutiérrez
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fmed.2021.743325
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Open Access Journals (DOAJ)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2296-858X
ExternalDocumentID oai_doaj_org_article_9dbcbe2f02bf4e5ab0937ede4fd923a4
PMC8450768
34552950
10_3389_fmed_2021_743325
Genre Journal Article
GrantInformation_xml – fundername: Vicerrectoría de Investigación, Universidad de Costa Rica
GroupedDBID 53G
5VS
9T4
AAFWJ
AAYXX
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
GROUPED_DOAJ
HYE
KQ8
M48
M~E
OK1
PGMZT
RPM
IAO
IEA
IHR
IHW
IPNFZ
ISR
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c462t-e34619f9c95aa9fb4c7cba6c4bba458688cd83d4cb88ff2f75528ea41938efa73
IEDL.DBID M48
ISSN 2296-858X
IngestDate Wed Aug 27 01:19:06 EDT 2025
Thu Aug 21 18:16:13 EDT 2025
Fri Jul 11 09:09:26 EDT 2025
Thu Jan 02 22:39:55 EST 2025
Thu Apr 24 23:01:20 EDT 2025
Tue Jul 01 03:03:22 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords COVID-19
SARS-CoV-2
heterologous antibodies
hyperimmune polyclonal antibodies
passive immunotherapy
convalescent plasma
monoclonal antibodies
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c462t-e34619f9c95aa9fb4c7cba6c4bba458688cd83d4cb88ff2f75528ea41938efa73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Zhiliang Hu, Nanjing Second Hospital, China
This article was submitted to Infectious Diseases - Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine
Reviewed by: Thierry Burnouf, Taipei Medical University, Taiwan; Leonardo M. R. Ferreira, Medical University of South Carolina, United States
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fmed.2021.743325
PMID 34552950
PQID 2575829188
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_9dbcbe2f02bf4e5ab0937ede4fd923a4
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8450768
proquest_miscellaneous_2575829188
pubmed_primary_34552950
crossref_citationtrail_10_3389_fmed_2021_743325
crossref_primary_10_3389_fmed_2021_743325
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-09-06
PublicationDateYYYYMMDD 2021-09-06
PublicationDate_xml – month: 09
  year: 2021
  text: 2021-09-06
  day: 06
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in medicine
PublicationTitleAlternate Front Med (Lausanne)
PublicationYear 2021
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Klassen (B7) 2021; 8
Vandeberg (B18) 2021; 61
Lopardo (B38) 2021; 34
Taylor (B10) 2021; 21
Da Costa (B33) 2021; 90
Cunha (B36) 2020
(B25) 2017
Dart (B28) 2019; 74
Scheinberg (B32) 2011; 365
León (B30) 2013; 76
Garcia-Beltran (B15) 2021; 184
Winkler (B11) 2021; 184
Zylberman (B35) 2020; 3
Epstein (B21) 2020; 115
Ali (B24) 2021; 36
Casadevall (B6) 2021; 12
Bolcato (B1) 2021; 9
Planas (B17) 2021; 596
Otero-Patiño (B27) 2012; 59
Goes (B4) 2021; 94
Mascarenas (B29) 2020; 186
Burnouf (B39) 2004; 32
Lazarevic (B13) 2021; 13
Liu (B20) 2021
Abubakar (B26) 2010; 4
Prévost (B16) 2021; 29
de Silva (B31) 2016; 81
Ferreira (B9) 2020; 5
Pan (B34) 2020; 182
Leon (B37) 2021; 11
Moreira-Soto (B40) 2021
Ainsworth (B23) 2020; 5
Harvey (B3) 2021; 19
Chen (B14) 2021; 27
Ali (B19) 2021; 13
Epstein (B22) 2021; 116
Mair-Jenkins (B5) 2015; 211
Kelley (B12) 2021; 8
Maxwell (B2) 2021
Epstein (B8) 2020; 5
References_xml – volume: 36
  start-page: 100926
  year: 2021
  ident: B24
  article-title: Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: a phase I/II randomized control trial
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2021.100926
– volume: 34
  start-page: 100843
  year: 2021
  ident: B38
  article-title: RBD-specific polyclonal F(ab')(2) fragments of equine antibodies in patients with moderate to severe COVID-19 disease: a randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial
  publication-title: EClinicalMedicine
  doi: 10.1016/j.eclinm.2021.100843
– volume: 81
  start-page: 446
  year: 2016
  ident: B31
  article-title: Adverse reactions to snake antivenom, and their prevention and treatment
  publication-title: Br J Clin Pharmacol
  doi: 10.1111/bcp.12739
– volume: 184
  start-page: 1804
  year: 2021
  ident: B11
  article-title: Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
  publication-title: Cell
  doi: 10.1016/j.cell.2021.02.026
– volume: 27
  start-page: 717
  year: 2021
  ident: B14
  article-title: Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
  publication-title: Nat Med
  doi: 10.1038/s41591-021-01294-w
– volume: 12
  start-page: e03372
  year: 2021
  ident: B6
  article-title: The principles of antibody therapy for infectious diseases with relevance for COVID-19
  publication-title: mBio
  doi: 10.1128/mBio.03372-20
– start-page: 1
  year: 2021
  ident: B20
  article-title: Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants
  publication-title: Hum Vaccin Immunother
  doi: 10.1080/21645515.2021.1940652
– volume: 5
  start-page: 115
  year: 2020
  ident: B23
  article-title: Animal derived antibodies should be considered alongside convalescent human plasma to deliver treatments for COVID-19
  publication-title: Wellcome Open Res
  doi: 10.12688/wellcomeopenres.15990.1
– volume: 5
  start-page: 103
  year: 2020
  ident: B8
  article-title: Plasma-based COVID-19 treatments in low-and middle-income countries and the risk of transfusion-transmitted infections
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-020-00256-6
– volume: 59
  start-page: 344
  year: 2012
  ident: B27
  article-title: Comparative study of the efficacy and safety of two polyvalent, caprylic acid fractionated [IgG and F(ab')2] antivenoms, in Bothrops asper bites in Colombia
  publication-title: Toxicon.
  doi: 10.1016/j.toxicon.2011.11.017
– volume: 116
  start-page: 13
  year: 2021
  ident: B22
  article-title: Use of COVID-19 convalescent plasma in low- and middle-income countries: a call for ethical principles and the assurance of quality and safety
  publication-title: Vox Sang
  doi: 10.1111/vox.12964
– volume: 74
  start-page: 439
  year: 2019
  ident: B28
  article-title: The efficacy of antivenin latrodectus (Black Widow) equine immune F(ab')(2) versus placebo in the treatment of latrodectism: a randomized, double-blind, placebo-controlled, clinical trial
  publication-title: Ann Emerg Med
  doi: 10.1016/j.annemergmed.2019.02.007
– year: 2020
  ident: B36
  article-title: Equine hyperimmune globulin raised against the SARS-CoV-2 spike glycoprotein has extremely high neutralizing titers
  publication-title: Preprint at bioRxiv.
– volume: 8
  start-page: 684151
  year: 2021
  ident: B7
  article-title: Convalescent plasma therapy for COVID-19: a graphical mosaic of the worldwide evidence
  publication-title: Front Med
  doi: 10.3389/fmed.2021.684151
– volume: 21
  start-page: 382
  year: 2021
  ident: B10
  article-title: Neutralizing monoclonal antibodies for treatment of COVID-19
  publication-title: Nat Rev Immunol
  doi: 10.1038/s41577-021-00542-x
– volume: 61
  start-page: 1705
  year: 2021
  ident: B18
  article-title: Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma
  publication-title: Transfusion
  doi: 10.1111/trf.16378
– volume: 186
  start-page: 42
  year: 2020
  ident: B29
  article-title: Comparison of F(ab')(2) and Fab antivenoms in rattlesnake envenomation: First year's post-marketing experience with F(ab')(2) in New Mexico
  publication-title: Toxicon.
  doi: 10.1016/j.toxicon.2020.08.002
– volume: 13
  start-page: 1192
  year: 2021
  ident: B13
  article-title: Immune evasion of SARS-CoV-2 emerging variants: what have we learnt so far?
  publication-title: Viruses
  doi: 10.3390/v13071192
– volume: 8
  start-page: e3139
  year: 2021
  ident: B12
  article-title: Process and operations strategies to enable global access to antibody therapies
  publication-title: Biotechnol Prog
  doi: 10.1002/btpr.3139
– volume: 3
  start-page: 1
  year: 2020
  ident: B35
  article-title: Development of a hyperimmune equine serum therapy for COVID-19 in Argentina
  publication-title: Medicina.
– volume: 115
  start-page: 485
  year: 2020
  ident: B21
  article-title: Points to consider in the preparation and transfusion of COVID-19 convalescent plasma
  publication-title: Vox Sang
  doi: 10.1111/vox.12939
– volume: 11
  start-page: 9825
  year: 2021
  ident: B37
  article-title: Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19
  publication-title: Sci Rep
  doi: 10.1038/s41598-021-89242-z
– volume: 4
  start-page: e767
  year: 2010
  ident: B26
  article-title: Randomised controlled double-blind non-inferiority trial of two antivenoms for saw-scaled or carpet viper (Echis ocellatus) envenoming in Nigeria
  publication-title: PLoS Negl Trop Dis
  doi: 10.1371/journal.pntd.0000767
– volume: 29
  start-page: 322
  year: 2021
  ident: B16
  article-title: The great escape? SARS-CoV-2 variants evading neutralizing responses
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2021.02.010
– volume: 211
  start-page: 80
  year: 2015
  ident: B5
  article-title: The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiu396
– volume: 596
  start-page: 276
  year: 2021
  ident: B17
  article-title: Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
  publication-title: Nature.
  doi: 10.1038/s41586-021-03777-9
– volume: 365
  start-page: 430
  year: 2011
  ident: B32
  article-title: Horse versus rabbit antithymocyte globulin in acquired aplastic anemia
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1103975
– volume: 19
  start-page: 409
  year: 2021
  ident: B3
  article-title: SARS-CoV-2 variants, spike mutations and immune escape
  publication-title: Nat Rev Microbiol
  doi: 10.1038/s41579-021-00573-0
– volume: 5
  start-page: 58
  year: 2020
  ident: B9
  article-title: Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic
  publication-title: NPJ Vaccines
  doi: 10.1038/s41541-020-0209-2
– volume: 182
  start-page: 104868
  year: 2020
  ident: B34
  article-title: Immunoglobulin fragment F(ab')2 against RBD potently neutralizes SARS-CoV-2 in vitro
  publication-title: Antiviral Res
  doi: 10.1016/j.antiviral.2020.104868
– volume: 32
  start-page: 115
  year: 2004
  ident: B39
  article-title: Assessment of the viral safety of antivenoms fractionated from equine plasma
  publication-title: Biologicals
  doi: 10.1016/j.biologicals.2004.07.001
– year: 2021
  ident: B2
  article-title: COVID-19 therapeutics for low- and middle-income countries: a review of candidate agents with potential for near-term use and impact
  publication-title: Am J Trop Med Hyg
  doi: 10.4269/ajtmh.21-0200
– volume-title: WHO Guidelines for the Production, Control and Regulation of Snake Antivenom Immunoglobulins
  year: 2017
  ident: B25
– volume: 184
  start-page: 2372
  year: 2021
  ident: B15
  article-title: Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
  publication-title: Cell.
  doi: 10.1016/j.cell.2021.03.013
– year: 2021
  ident: B40
  article-title: High efficacy of therapeutic equine hyperimmune antibodies against SARS-CoV-2 variants of concern
  publication-title: Preprint at bioRxiv.
  doi: 10.1101/2021.06.12.448080
– volume: 9
  start-page: 538
  year: 2021
  ident: B1
  article-title: COVID-19 pandemic and equal access to vaccines
  publication-title: Vaccines
  doi: 10.3390/vaccines9060538
– volume: 94
  start-page: 104998
  year: 2021
  ident: B4
  article-title: New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil
  publication-title: Infect Genet Evol
  doi: 10.1016/j.meegid.2021.104998
– volume: 76
  start-page: 63
  year: 2013
  ident: B30
  article-title: Pathogenic mechanisms underlying adverse reactions induced by intravenous administration of snake antivenoms
  publication-title: Toxicon.
  doi: 10.1016/j.toxicon.2013.09.010
– volume: 13
  start-page: 397
  year: 2021
  ident: B19
  article-title: Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma
  publication-title: Immunotherapy.
  doi: 10.2217/imt-2020-0263
– volume: 90
  start-page: 107220
  year: 2021
  ident: B33
  article-title: COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2020.107220
SSID ssj0001325413
Score 2.2189178
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 743325
SubjectTerms convalescent plasma
COVID-19
heterologous antibodies
hyperimmune polyclonal antibodies
Medicine
passive immunotherapy
SARS-CoV-2
SummonAdditionalLinks – databaseName: Open Access Journals (DOAJ)
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQD4gLojzDozISF6SGbhzbsbmlC9UWqYBYWvUW-VlWWpIKpYf9G_3FnXHS1S5CcOESKYkdW57xeCbz-TMhb5DUbaIrk1stbc4dXAxzOudBCmud8QOX3slnOTvln87F-cZRX4gJG-iBh4E70N46G1icMBt5EMZCCF4FH3j04JuYxAQKa95GMJX-rpQQ-BTlkJeEKEyDmAISg7LiXYWUXWJrHUp0_X_yMX-HSm6sPUcPyP3RaaT10Nldcie0D8ndkzEt_ohczxDUgmYM4ng6WyXS_p9XbaBfu-XKLbtUu-0XtkPQIK0vzALcQjqvv83zaXeWs_e0phCRG0-niOkEI7NP64jAd9xatU9N6-kcxIl38NEeMUbwzWNsZdzDtaJQnE6_nB1_yAv9mJweffw-neXjYQu545L1eSg5xFJROy2M0dFyVzlrpOPWGi6UVMp5VXrurFIxslgJwVQwHBxAFaKpyidkp-3a8IxQLkJZWMRUlRW30hswI4wrrXjpJThsGTm4HfrGjUzkeCDGsoGIBIXVoLAaFFYzCCsjb9c1LgcWjr-UPURprsshf3Z6AFrVjFrV_EurMvL6VhcamG-YRDFtABk2YOKEYrpQKiNPB91YN1VygXnTSUaqLa3Z6sv2m3bxI3F6Ky4wJ_r8f3T-BbmH45GQcPIl2el_XYVX4Dr1di_NkhtG9Bow
  priority: 102
  providerName: Directory of Open Access Journals
Title Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19
URI https://www.ncbi.nlm.nih.gov/pubmed/34552950
https://www.proquest.com/docview/2575829188
https://pubmed.ncbi.nlm.nih.gov/PMC8450768
https://doaj.org/article/9dbcbe2f02bf4e5ab0937ede4fd923a4
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bi9QwFA66gvgi3rdelgi-CJt1Jk3aRBCpo8usMCqOs8xbyXUdGFsdu-D8DX-x57Td0ZFBfCm0SZM2J5fv5Jx8h5AnSOo20LlhVmeWCQcXw51mImTSWmd8x6U3eZeNZ-LtXM5_H4_uG_D7TtUO40nNVsujH9_WL2HAv0CNE9ZbkEBAzk8-PMqRjUteJldgXcoxnsGkB_vtjgskiTZeMuc6Y0qqeWe33FnI1jrV0vnvwqB_u1L-sTYd3yDXe1BJi64X3CSXQnWLXJ30ZvPb5OcYnV5wmgM9n47XLan_l_Mq0A_1cu2Wdft21SxsjU6FtDgzC4CNdFp8nLJRfcr4c1pQ0NiNpyP0-YRJ6JAWER3j8ejVITWVp1MQN95BoQ36IEGZJ1hLf8ZrTSE7Hb0_PXnNhvoOmR2_-TQasz4YA3Mi4w0LqQBdK2qnpTE6WuFyZ03mhLVGSJUp5bxKvXBWqRh5zKXkKhgBAFGFaPL0Ltmr6irsEypkSIcWfa7SXNjMG5hmuFBaidRnAOgS8uyi6UvXM5VjwIxlCRoLCqtEYZUorLITVkKebt742rF0_CPvK5TmJh_ya7cP6tVZ2Q_XUnvrbOBxwG0UQRo7ABgXfBDRAyI2IiGPL_pCCeMRjSymCiDDEqZAqbgeKpWQe13f2FSVCol21UFC8q1es_Ut2ynV4nPL-a2ERJvp_f-o9wG5hr_bOsJlD8leszoPjwA5Nfag3XE4aIfFLyneGDc
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Heterologous+Hyperimmune+Polyclonal+Antibodies+Against+SARS-CoV-2%3A+A+Broad+Coverage%2C+Affordable%2C+and+Scalable+Potential+Immunotherapy+for+COVID-19&rft.jtitle=Frontiers+in+medicine&rft.au=Alape-Gir%C3%B3n%2C+Alberto&rft.au=Moreira-Soto%2C+Andr%C3%A9s&rft.au=Arguedas%2C+Mauricio&rft.au=Brenes%2C+Hebleen&rft.date=2021-09-06&rft.issn=2296-858X&rft.eissn=2296-858X&rft.volume=8&rft.spage=743325&rft_id=info:doi/10.3389%2Ffmed.2021.743325&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2296-858X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2296-858X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2296-858X&client=summon